Jasper Therapeutics reported clinical updates on its briquilimab studies targeting chronic spontaneous urticaria (CSU). While Phase 1b/2a BEACON data showed high complete response rates with briquilimab in CSU, the company identified issues with a drug product lot that affected other cohorts and an asthma trial. Due to these drug batch problems, Jasper Therapeutics decided to stop the ETESIAN study and terminate its asthma and SCID programs, implementing cost-cutting measures to focus on CSU. Following the announcement, Jasper's stock dropped by 64.6%. Separately, AstraZeneca disclosed that its experimental drug anselamimab failed to meet the primary endpoint in a late-stage study for AL amyloidosis, a rare disease characterized by protein deposits in the body. The therapy did not delay deaths or reduce hospitalizations in severe cases, with the drug missing primary endpoints in two Phase 3 trials. AstraZeneca noted potential in an unnamed subgroup but provided no further details. In contrast, Cue Biopharma reported promising results from an ongoing Phase 1 trial of CUE-101 combined with pembrolizumab in recurrent or metastatic HPV-positive head and neck cancer. The trial showed a 50% overall response rate and an 88% survival rate, even in patients with low PD-L1 expression. Additionally, Quince Therapeutics announced the completion of enrollment in its pivotal Phase 3 NEAT clinical trial for ataxia-telangiectasia.